# Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Study · id `cardio:ct-nct05186818` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05186818](<https://clinicaltrials.gov/study/NCT05186818>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05186818

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.

## Technical summary

Registry record NCT05186818. Randomized; double masking; primary purpose treatment. Start 2022-02-01 (actual); primary completion 2023-11-10 (actual). Results posted on 2026-03-03.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 282 participants (enrolled count; ClinicalTrials.gov record NCT05186818, source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)
- Started: 2022-02-01 (actual) (ClinicalTrials.gov record NCT05186818, source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)
- Primary completion: 2023-11-10 (actual) (ClinicalTrials.gov record NCT05186818, source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)
- Completion: 2023-12-18 (actual) (ClinicalTrials.gov record NCT05186818, source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)
- Results first posted: 2026-03-03 (ClinicalTrials.gov record NCT05186818, source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)
- Countries: United States; China; Czechia; Denmark; France; Germany; Hungary; Israel; Italy; Netherlands; Poland; Portugal; Spain; United Kingdom (ClinicalTrials.gov record NCT05186818, source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05186818-2026-03-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
- Acronym: SEQUOIA-HCM
- Condition: Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Intervention (Drug): Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- Intervention (Drug): Placebo to match aficamten
- Lead sponsor: Cytokinetics
- Lead sponsor class: INDUSTRY
- Collaborator: Corxel Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Cytokinetics (`cardio:org-cytokinetics`)
- Registry lists this organization as a collaborator: Corxel Pharmaceuticals (`cardio:org-corxel-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (`cardio:pubmed-38739079`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM (`cardio:pubmed-39056349`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial (`cardio:pubmed-39230885`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy (`cardio:pubmed-39217556`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy (`cardio:pubmed-39217563`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM (`cardio:pubmed-39217569`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM (`cardio:pubmed-39352339`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial (`cardio:pubmed-39217447`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants (`cardio:pubmed-40200648`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial (`cardio:pubmed-40910168`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 45d8de95816943d08ade1e7b63bf087ba46e4bc3c1405b7967ef7562ca0c6456
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
